A Competitive Ligand-Binding Assay for Simultaneous Detection of Neutralizing Antibodies to Both Arms of a Bispecific Drug.

Vitaly Ablamunits, Soma Basak, Rosemary Lawrence-Henderson, Teresa M Caiazzo, John Kamerud

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vitaly AblamunitsPharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Andover, MA, USA. Vitaly.Ablamunits@pfizer.com.

Soma BasakPharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Andover, MA, USA.

Rosemary Lawrence-HendersonPharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Andover, MA, USA.

Teresa M CaiazzoPharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Andover, MA, USA.

John KamerudPharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Andover, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bispecific monoclonal antibodies gain their attractiveness as a novel class of drugs that are capable of neutralizing two or more cytokines simultaneously or activate hetero-dimeric cell receptors. Monitoring appearance of neutralizing antibodies (NAbs) to these drugs is a challenging task. Here, we report a competitive ligand- binding assay (CLBA) for detection of NAbs to a bispecific candidate drug using a multiplex Meso Scale Discovery (MSD) platform, which allows for detection of NAbs to both drug arms in the same sample. The assay has sensitivity better than 250 ng/mL, is tolerant to the presence of drug at concentration > 600 μg/mL, and to the level of soluble target(s) >400 ng/mL. Thus, multiplex approach provided by MSD platform can be successfully used for development of NAb assays in competitive ligand-binding assay format.

Indexed as

Antibodies, BispecificAntibodies, NeutralizingAntibodies, MonoclonalBinding, CompetitiveHumansLigandsProtein BindingAntibodies, BispecificAntibodies, MonoclonalAntibodies, NeutralizingLigandsBispecific drugCompetitive ligand-binding assayNeutralizing antibodiesU-plex MSD

Identifiers

PMID40601151

DOI10.1016/j.yrtph.2007.07.005

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.